PBSV Pharma-Bio Serv

Pharma-Bio Serv is a compliance, project management, and technology transfer support consulting firm, headquartered in Puerto Rico, with operations in the U.S., Ireland, and Spain. Pharma-Bio Serv's core business is FDA and other international regulatory compliance agency related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Company profile

Victor Sanchez
Fiscal year end
Former names
IRS number

PBSV stock data



17 Mar 21
14 Jun 21
31 Oct 21
Quarter (USD)
Jan 21 Oct 20 Jul 20 Apr 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Oct 20 Oct 19 Oct 18 Oct 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Mar 21 Plaza Elizabeth Common Stock Sell Dispose S No No 1.0965 230,000 252.2K 3,869,241
10 Jan 21 Howard Spindel Stock Option Common Stock Grant Aquire A No No 1.4 20,000 28K 20,000
10 Jan 21 Perlysky Dov Stock option Common stock Grant Aquire A No No 1.4 20,000 28K 20,000
10 Jan 21 Kirk Wheeler Michel Stock Option Common Stock Grant Aquire A No No 1.4 20,000 28K 20,000
10 Jan 21 Irving L Wiesen Stock option Common stock Grant Aquire A No No 1.4 20,000 28K 20,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

  • Because our business is concentrated in the life science and medical devices industries in Puerto Rico, the United States, Europe and Brazil, any changes in those industries or in those markets could impair our ability to generate revenue and realize a profit.
  • Puerto Rico’s economy, including its governmental financial crisis and the impact of hurricanes or any other natural disasters, including recent earthquakes, may affect the willingness of businesses to commence or expand operations in Puerto Rico, or may also consider closing operations located in Puerto Rico.
  • Because our business is dependent upon a small number of clients, the loss of a major client could impair our ability to operate profitably.
  • Customer procurement and sourcing practices intended to reduce costs could have an adverse effect on our margins and profitability.
  • We may be unable to pass on increased labor costs to our clients.
  • Consolidation in the pharmaceutical industry may have a harmful effect on our business.
  • We may be held liable for the actions of our employees or contractors when on assignment.
  • To the extent that we perform services pursuant to fixed-price or incentive-based contracts, our cost of services may exceed our revenue on the contract.
  • Because most of our contracts may be terminated on little or no advance notice, our failure to generate new business could impair our ability to operate profitably.
  • Because we are dependent upon our management and technical personnel, our ability to develop our business may be impaired if we are not able to engage skilled personnel.
  • Our cash could be adversely affected if the financial institutions in which we hold our cash fail.
  • We may be harmed if we do not penetrate markets and grow our current business operations.
  • Puerto Rico government enacted ACT 154-2010 may adversely affect the willingness of our customers to do business in Puerto Rico and consequently adversely affect our business.
  • Because the pharmaceutical industry is subject to government regulations, changes in government regulations relating to this industry may affect the need for our services.
  • Our CARES Act loan may be subject to regulatory review resulting from unclear subjective and objective eligibility requirements for the loan.
  • Since our business is dependent upon the development and enhancement of patented pharmaceutical products or processes by our clients, the failure of our clients to obtain and maintain patents could impair our ability to operate profitably.
  • If we are unable to protect our clients’ intellectual property, our ability to generate business will be impaired.
  • We may be subject to liability if our services or solutions for our clients infringe upon the intellectual property rights of others.
  • Because there is a limited market in our common stock, stockholders may have difficulty in selling our common stock and our common stock may be subject to significant price swings.
  • Our revenues, operating results and profitability will vary from quarter to quarter, which may result in increased volatility of our stock price.
  • The Company Stock Repurchase Program could affect the market price of our common stock and increase its volatility.
  • The issuance of securities, whether in connection with an acquisition or otherwise, may result in significant dilution to our stockholders.
Management Discussion
  • Revenues. Revenues for the year ended October 31, 2020 were $21.6 million, an increase of $2.1 million when compared to the last year. The increase is attributable to an increase in projects in Puerto Rico, US, European and Latin American markets of approximately $1,417,000, $95,000, $514,000 and $31,000, respectively.
  • Cost of Services; gross profit. Cost of services were $14.9 million, an increase of $1.6 million when compared to last year. The overall gross profit for the year ended October 31, 2020 reflected a gross profit decrease of 0.8 percentage points, when compared to last year. The variance in gross profit is mainly attributable to current fiscal year’s less favorable consulting projects in the Puerto Rico consulting market.
  • Selling, General and Administrative Expenses. Selling, general and administrative expenses for the year ended in October 31, 2020 were approximately $4.4 million, which is comparable to selling, general and administrative expenses reported by the Company last year.
Content analysis
H.S. freshman Avg
New words: agreed, alternative, ASC, brought, case, Codification, Commonwealth, complaint, contractor, court, declared, defend, director, District, enforceable, fee, formatted, higher, injunctive, inline, insignificant, Interactive, iv, leading, merit, monetary, page, removed, resignation, resolved, resume, SCI, separate, short, sought, transaction, vigorously
Removed: annually, arising, ASU, China, clarifying, comparability, comparative, consideration, Council, deliver, demand, difficult, disaster, disclose, discount, disposition, distinction, diversity, division, entitled, epidemic, expired, fall, greater, growth, Hubei, immaterial, implementation, improvement, Initiative, Irish, Irma, July, line, Maria, National, negatively, NMSDC, optional, orderly, participate, proportional, Province, qualitative, quantitative, renewal, restated, retrospective, strain, strategy, submit, subsequently, Supplier, Targeted, threshold, transferred, transparency, twelve, unchanged, workforce, Wuhan